McKesson (MCK)
(Delayed Data from NYSE)
$607.51 USD
+58.20 (10.60%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$607.51 USD
+58.20 (10.60%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Zacks.com featured highlights include TotalEnergies, J.B. Hunt Transport Services, Archer-Daniels-Midland , McKesson and Republic Services
by Zacks Equity Research
TotalEnergies, J.B. Hunt Transport Services, Archer-Daniels-Midland , McKesson and Republic Services are part of Zacks Screen of the Week article.
Henry Schein (HSIC) Inks Deal to Acquire Midway Dental Supply
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Midway Dental Supply complements its efforts to offer products and services that deliver more effective, high-quality patient care.
Here's Why You Should Retain AngioDynamics (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) continues to benefit from strength in segments but forex remains a woe.
5 Dividend Growth Stocks to Beat September Slump
by Sweta Killa
Dividend growth stocks like TotalEnergies, J.B. Hunt, Archer-Daniels-Midland, McKesson and Republic Services seem like solid choices for September.
Bruker (BRKR) Debuts Innovations for Proteomics & Metabolomics
by Zacks Equity Research
Bruker's (BRKR) novel nanoElute 2 and next-generation MetaboScape 2023 release are likely to offer enhanced workflows for proteomics and metabolomics applications.
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.
Haemonetics (HAE) Inks Epic Deal to Expand Hospital Business
by Zacks Equity Research
According to Haemonetics (HAE), amid the complex situation of blood supply and staffing shortages, the SafeTrace Tx transfusion management system is set to provide more transfusion safety and efficiency.
Catalent (CTLT) Stock Down Despite Q4 Beat: Will it Recover?
by Zacks Equity Research
Catalent's (CTLT) fiscal fourth-quarter earnings beat but the stock falls 7.4% following the earnings release on Aug 29. Here we discuss the factors that are set to guide its share price going forward.
Here's Why You Should Hold on to Nevro (NVRO) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.
Teladoc Health (TDOC) Ties Up to Upgrade RPM Care in Canada
by Zacks Equity Research
Teladoc Health (TDOC) teams up with Cloud DX to bring its virtual care capabilities to the latter's platform and dispense advanced RPM solutions to the Canadian residents.
Myriad Genetics (MYGN) Gets Extensive Coverage for BRACAnalysis
by Zacks Equity Research
Myriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer patients who are eligible for treatment with Lynparza in Japan.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
What's in Store for Patterson Companies (PDCO) in Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at the Animal Health segment.
Catalent (CTLT) Q4 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its fourth-quarter fiscal 2022 top line.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Here's Why Investors Should Retain Myriad Genetics (MYGN) Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics' (MYGN) better-than-expected results and strong testing volumes.
Is McKesson (MCK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Veeva Systems (VEEV) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) Q2 earnings are likely to have been driven by strength in its commercial business.
Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.
Fresenius Medical (FMS) Robust Product Portfolio Drives Growth
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Catalent (CTLT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q4 results are likely to have been driven by robust segmental performances.
3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Phibro (PAHC) Q4 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Phibro (PAHC) posts better-than-expected revenues for the fiscal fourth quarter, with robust growth across all segments.
3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Abbott (ABT) to Offer New Treatment Option for Chronic Pain
by Zacks Equity Research
Abbott's (ABT) Proclaim Plus SCS system with FlexBurst360 therapy will cater to the changing needs of patients with chronic pain.